Paul Anderson is a Non-Executive Director of Marine Biomedical with more than 20 years of experience in the medical device and cellular therapeutics sectors. His career has focused on bridging the gap between scientific research and clinical application, particularly in the development and commercialisation of emerging medical technologies. Paul’s expertise spans regulatory strategy, reimbursement pathways, marketing, sales, financial planning, and the cultivation of key opinion leader networks, capabilities that have supported the successful translation of multiple advanced therapies into clinical practice. He previously served on the board of Verigen Australia Pty Ltd, a human cell therapies company, where he contributed to the growth and governance of one of the early pioneers in the regenerative medicine field.

In his role at Marine Biomedical, Paul provides strategic oversight and industry insight to support the company’s expansion into global medtech markets. His deep understanding of commercialisation pathways and clinical adoption challenges strengthens the company’s ability to navigate regulatory environments and position PearlBone™ for long-term success. Paul’s track record in guiding innovative medical technologies from concept to clinic, combined with his strategic and financial acumen, makes him a valuable contributor to Marine Biomedical’s mission to deliver high-quality, evidence-based biomaterials to surgeons and patients worldwide.